Table 1.

Key clinical trials evaluating the use of fospropofol as an agent in MAC sedation.

Study	n	Procedure	Pretreatment	Dose (mg/kg) of fospropofol	Other agents?	Conclusions
Cohen 2008 [69]	127	Colonoscopy	50 μg fentanyl	2, 5, 6.5, or 8.0	Midazolam as reference (0.02 mg/kg)	Significant dose-dependent increases in sedation
Cohen et al. 2010 [70]	314	Colonoscopy	50 μg fentanyl	2.0 or 6.5	Midazolam (0.02 mg/kg)	Significantly greater sedation success, greater memory retention, and higher physician satisfaction at 6.5 than 2.0 mg/kg of fospropofol
Silvestri et al. 2009 [71]	252	Flexible bronchoscopy	50 μg fentanyl	2 or 6.5	No	Significantly higher sedation success at 6.5 mg/kg (88.7% versus 27.5%, P < .001)
Rex et al. 2007, Safety and Efficacy [72]	314	Colonoscopy	50 μg fentanyl	2.0 or 6.5	Midazolam (0.02 mg/kg)	Significantly higher sedation success at 6.5 mg/kg (87% versus 26%, P < .001) with significantly greater depth of sedation
Rex et al. 2007, Clear-headed recovery [73]	314	Colonoscopy	50 μg fentanyl	2.0 or 6.5	Midazolam (0.02 mg/kg)	Fospropofol patients (both doses) had significantly higher mean percentage of retention postprocedure than midazolam (P < .001)